MBL Japan Files For Approval Of Diagnostic Agent For EGFR Antibody Drug
This article was originally published in PharmAsia News
Medical&Biological Laboratories Japan has, in collaboration with its subsidiary G&G Science, filed for the approval of a diagnostic agent for use in conjunction with anti-EGFR antibody drugs used in colorectal cancer treatment, the company announced on June 19.
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.